Adalgisa Condoluci1,2, Davide Rossi3,4. 1. Division of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland. 2. Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland. 3. Division of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland. davide.rossi@eoc.ch. 4. Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland. davide.rossi@eoc.ch.
Abstract
PURPOSE OF REVIEW: Richter syndrome (RS) is an uncommon but aggressive evolution of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). RS is an unmet clinical need in the field of CLL. Recent advances in understanding the biology of this condition provide the rationale for testing new therapeutic concepts in order to improve the outcome of patients developing RS, which is so far poor. In this review, we summarize disease characteristics and available therapeutic options for RS. RECENT FINDINGS: Current regimens with novel agents in monotherapy have shown little impact on survival. Nevertheless, the better reported outcome for RS has been achieved with the combination of chemo-immunotherapy with a novel agent, confirming the synergistic effect of the approaches. Still, the frailty of this population may impose a less toxic management leaving most patients with no reasonable therapeutic option. Treatment options for RS need to be further expanded. Preclinical models in current development may allow to explore actionable pathways and identify new drug targeted combinations.
PURPOSE OF REVIEW: Richter syndrome (RS) is an uncommon but aggressive evolution of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). RS is an unmet clinical need in the field of CLL. Recent advances in understanding the biology of this condition provide the rationale for testing new therapeutic concepts in order to improve the outcome of patients developing RS, which is so far poor. In this review, we summarize disease characteristics and available therapeutic options for RS. RECENT FINDINGS: Current regimens with novel agents in monotherapy have shown little impact on survival. Nevertheless, the better reported outcome for RS has been achieved with the combination of chemo-immunotherapy with a novel agent, confirming the synergistic effect of the approaches. Still, the frailty of this population may impose a less toxic management leaving most patients with no reasonable therapeutic option. Treatment options for RS need to be further expanded. Preclinical models in current development may allow to explore actionable pathways and identify new drug targeted combinations.
Authors: Tiziana Vaisitti; Esteban Braggio; John N Allan; Francesca Arruga; Sara Serra; Alberto Zamò; Wayne Tam; Amy Chadburn; Richard R Furman; Silvia Deaglio Journal: Cancer Res Date: 2018-05-07 Impact factor: 12.701
Authors: Wei Ding; Betsy R LaPlant; Timothy G Call; Sameer A Parikh; Jose F Leis; Rong He; Tait D Shanafelt; Sutapa Sinha; Jennifer Le-Rademacher; Andrew L Feldman; Thomas M Habermann; Thomas E Witzig; Gregory A Wiseman; Yi Lin; Erik Asmus; Grzegorz S Nowakowski; Michael J Conte; Deborah A Bowen; Casey N Aitken; Daniel L Van Dyke; Patricia T Greipp; Xin Liu; Xiaosheng Wu; Henan Zhang; Charla R Secreto; Shulan Tian; Esteban Braggio; Linda E Wellik; Ivana Micallef; David S Viswanatha; Huihuang Yan; Asher A Chanan-Khan; Neil E Kay; Haidong Dong; Stephen M Ansell Journal: Blood Date: 2017-04-19 Impact factor: 22.113
Authors: Lorenzo Falchi; Michael J Keating; Edith M Marom; Mylene T Truong; Ellen J Schlette; Rachel L Sargent; Long Trinh; Xuemei Wang; Susan C Smith; Nitin Jain; Zeev Estrov; Susan O'Brien; William G Wierda; Susan Lerner; Alessandra Ferrajoli Journal: Blood Date: 2014-03-10 Impact factor: 22.113
Authors: Idit Sagiv-Barfi; Holbrook E K Kohrt; Debra K Czerwinski; Patrick P Ng; Betty Y Chang; Ronald Levy Journal: Proc Natl Acad Sci U S A Date: 2015-02-17 Impact factor: 11.205
Authors: Apostolia-Maria Tsimberidou; Susan O'Brien; Hagop M Kantarjian; Charles Koller; Fredrick B Hagemeister; Luis Fayad; Susan Lerner; Carlos E Bueso-Ramos; Michael J Keating Journal: Cancer Date: 2006-09-15 Impact factor: 6.860
Authors: Apostolia M Tsimberidou; William G Wierda; Sijin Wen; William Plunkett; Susan O'Brien; Thomas J Kipps; Jeffrey A Jones; Xavier Badoux; Hagop Kantarjian; Michael J Keating Journal: Clin Lymphoma Myeloma Leuk Date: 2013-06-27
Authors: Yandong Shen; Luke Coyle; Ian Kerridge; William Stevenson; Christopher Arthur; Naomi McKinlay; Keith Fay; Christopher Ward; Matthew Greenwood; Oliver Giles Best; Ann Solterbeck; Alexander Guminski; Stephen Shumack; Stephen P Mulligan Journal: EJHaem Date: 2021-12-13
Authors: Martin Dreyling; Marc André; Nicola Gökbuget; Hervé Tilly; Mats Jerkeman; John Gribben; Andrés Ferreri; Pierre Morel; Stephan Stilgenbauer; Christopher Fox; José Maria Ribera; Sonja Zweegman; Igor Aurer; Csaba Bödör; Birgit Burkhardt; Christian Buske; Maria Dollores Caballero; Elias Campo; Bjoern Chapuy; Andrew Davies; Laurence de Leval; Jeanette Doorduijn; Massimo Federico; Philippe Gaulard; Francesca Gay; Paolo Ghia; Kirsten Grønbæk; Hartmut Goldschmidt; Marie-Jose Kersten; Barbara Kiesewetter; Judith Landman-Parker; Steven Le Gouill; Georg Lenz; Sirpa Leppä; Armando Lopez-Guillermo; Elizabeth Macintyre; Maria Victoria Mateos Mantega; Philippe Moreau; Carol Moreno; Bertrand Nadel; Jessica Okosun; Roger Owen; Sarka Pospisilova; Christiane Pott; Tadeusz Robak; Michelle Spina; Kostas Stamatopoulos; Jan Stary; Karin Tarte; Allessandra Tedeschi; Catherine Thieblemont; Ralf Ulrich Trappe; Lorenz H Trümper; Gilles Salles Journal: Hemasphere Date: 2022-05-19
Authors: Paolo Sportoletti; Filomena De Falco; Beatrice Del Papa; Stefano Baldoni; Valerio Guarente; Andrea Marra; Erica Dorillo; Chiara Rompietti; Francesco Maria Adamo; Loredana Ruggeri; Mauro Di Ianni; Emanuela Rosati Journal: Int J Mol Sci Date: 2021-06-22 Impact factor: 5.923
Authors: Andrea Visentin; Laura Bonaldi; Gian Matteo Rigolin; Francesca Romana Mauro; Annalisa Martines; Federica Frezzato; Stefano Pravato; Leila Romano Gargarella; Maria Antonella Bardi; Maurizio Cavallari; Eleonora Volta; Francesco Cavazzini; Mauro Nanni; Monica Facco; Francesco Piazza; Anna Guarini; Robin Foà; Gianpietro Semenzato; Antonio Cuneo; Livio Trentin Journal: Haematologica Date: 2022-04-01 Impact factor: 9.941